



**Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2014
Table of Contents**

Table 1: GAAP P&L.....	1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.....	2
Table 2a: GAAP to Non-GAAP P&L Reconciliation 3Q14	3
Table 2b: GAAP to Non-GAAP P&L Reconciliation Sep YTD 14.....	4
Table 2c: GAAP to Non-GAAP P&L Reconciliation 3Q13.....	5
Table 2d: GAAP to Non-GAAP P&L Reconciliation Sep YTD 13.....	6
Table 3: Sales – Current Year and Prior Year by Quarter	7
Table 3a: Sales – U.S. / Ex- U.S. 3Q14	8
Table 3b: Sales – U.S. / Ex- U.S. Sep YTD 14	9
Table 3c: Sales – Pharmaceutical Geographic Split	10
Table 4: Equity Income / JV Sales / Other (Income) Expense	11

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

	GAAP		% Change	GAAP		% Change
	3Q14	3Q13		Sep YTD 2014	Sep YTD 2013	
Sales	\$ 10,557	\$ 11,032	-4%	\$ 31,755	\$ 32,713	-3%
Costs, Expenses and Other						
Materials and production ⁽¹⁾	4,223	4,104	3%	13,019	12,347	5%
Marketing and administrative ⁽¹⁾	2,975	2,803	6%	8,681	8,929	-3%
Research and development ⁽¹⁾	1,659	1,660	--	4,897	5,668	-14%
Restructuring costs ⁽²⁾	376	870	-57%	664	1,144	-42%
Equity income from affiliates ⁽³⁾	(24)	(102)	-76%	(241)	(351)	-31%
Other (income) expense, net ^{(1) (4)}	(142)	172	*	(737)	656	*
Income Before Taxes	1,490	1,525	-2%	5,472	4,320	27%
Income Tax Provision	648	375		865	618	
Net Income	842	1,150	-27%	4,607	3,702	24%
Less: Net (Loss) Income Attributable to Noncontrolling Interests	(53)	26		3	79	
Net Income Attributable to Merck & Co., Inc.	\$ 895	\$ 1,124	-20%	\$ 4,604	\$ 3,623	27%
Earnings per Common Share Assuming Dilution	\$ 0.31	\$ 0.38	-18%	\$ 1.57	\$ 1.20	31%
Average Shares Outstanding Assuming Dilution	2,911	2,960		2,942	3,007	
Tax Rate ⁽⁵⁾	43.5%	24.6%		15.8%	14.3%	

* 100% or greater

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(3) Reflects the performance of the company's joint ventures and other equity method affiliates, including the Sanofi Pasteur MSD partnership, as well as the AstraZeneca LP partnership until its termination on June 30, 2014.

(4) Other (income) expense, net in the third quarter and first nine months of 2014 includes a gain of \$396 million on the divestiture of certain ophthalmic products in several international markets, partially offset by a \$93 million goodwill impairment charge related to the company's joint venture with Supera Farma Laboratorios S.A. Other (income) expense, net in the first nine months of 2014 also includes a gain of \$741 million related to AstraZeneca's option exercise and net gains of \$168 million related to the divestiture of the company's Sirna Therapeutics, Inc. subsidiary. Other (income) expense, net in the first nine months of 2013 reflects approximately \$140 million of exchange losses as a result of a Venezuelan currency devaluation.

(5) The effective income tax rate for the first nine months of 2014 reflects a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise, as well as a benefit of approximately \$300 million associated with a capital loss generated in the first quarter of 2014.

The effective income tax rate for the first nine months of 2013 reflects net benefits from the settlements of certain federal income tax issues, reductions in tax reserves upon expiration of applicable statute of limitations and the favorable impact of tax legislation enacted in the first quarter of 2013.

CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1a

	2014				2013						% Change	
	1Q	2Q	3Q	Sep YTD	1Q	2Q	3Q	Sep YTD	4Q	Full Year	3Q	Sep YTD
Sales	\$ 10,264	\$ 10,934	\$ 10,557	\$ 31,755	\$ 10,671	\$ 11,010	\$ 11,032	\$ 32,713	\$ 11,319	\$ 44,033	-4%	-3%
Costs, Expenses and Other												
Materials and production	3,903	4,893	4,223	13,019	3,959	4,284	4,104	12,347	4,607	16,954	3%	5%
Marketing and administrative	2,734	2,973	2,975	8,681	2,987	3,140	2,803	8,929	2,982	11,911	6%	-3%
Research and development	1,574	1,664	1,659	4,897	1,907	2,101	1,660	5,668	1,836	7,503	--	-14%
Restructuring costs	125	163	376	664	119	155	870	1,144	565	1,709	-57%	-42%
Equity income from affiliates	(124)	(92)	(24)	(241)	(133)	(116)	(102)	(351)	(53)	(404)	-76%	-31%
Other (income) expense, net	(39)	(558)	(142)	(737)	282	201	172	656	157	815	*	*
Income Before Taxes	2,091	1,891	1,490	5,472	1,550	1,245	1,525	4,320	1,225	5,545	-2%	27%
Income Tax Provision (Benefit)	360	(142)	648	865	(66)	310	375	618	410	1,028		
Net Income	1,731	2,033	842	4,607	1,616	935	1,150	3,702	815	4,517	-27%	24%
Less: Net Income (Loss) Attributable to Noncontrolling Interests	26	29	(53)	3	23	29	26	79	34	113		
Net Income Attributable to Merck & Co., Inc.	\$ 1,705	\$ 2,004	\$ 895	\$ 4,604	\$ 1,593	\$ 906	\$ 1,124	\$ 3,623	\$ 781	\$ 4,404	-20%	27%
Earnings per Common Share Assuming Dilution	\$ 0.57	\$ 0.68	\$ 0.31	\$ 1.57	\$ 0.52	\$ 0.30	\$ 0.38	\$ 1.20	\$ 0.26	\$ 1.47	-18%	31%
Average Shares Outstanding Assuming Dilution	2,971	2,949	2,911	2,942	3,053	3,010	2,960	3,007	2,959	2,996		
Tax Rate	17.2%	-7.5%	43.5%	15.8%	-4.3%	24.9%	24.6%	14.3%	33.5%	18.5%		

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2a

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 10,557					\$ 10,557
Costs, Expenses and Other						
Materials and production	4,223	1,420	87		1,507	2,716
Marketing and administrative	2,975	110	68	193	371	2,604
Research and development	1,659	36	81		117	1,542
Restructuring costs	376		376		376	-
Equity income from affiliates	(24)					(24)
Other (income) expense, net	(142)	93		(391)	(298)	156
Income Before Taxes	1,490	(1,659)	(612)	198	(2,073)	3,563
Taxes on Income	648				(295) ⁽⁴⁾	943
Net Income	842				(1,778)	2,620
Less: Net (Loss) Income Attributable to Noncontrolling Interests	(53)	(56)			(56)	3
Net Income Attributable to Merck & Co., Inc.	\$ 895				\$ (1,722)	\$ 2,617
Earnings per Common Share Assuming Dilution	\$ 0.31					\$ 0.90
Average Shares Outstanding Assuming Dilution	2,911					2,911
Tax Rate	43.5%					26.5%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$1.0 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$412 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges primarily related to the company's joint venture with Supera. Amount included in other (income) expense, net represents a goodwill impairment charge related to the joint venture with Supera. Amount included in net (loss) income attributable to non-controlling interests represents the portion of intangible asset and goodwill impairment charges related to the joint venture with Supera that are attributable to non-controlling interests.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Amount included in marketing and administrative expenses represents an additional year of expense related to the healthcare reform fee in accordance with final regulations issued in the third quarter by the Internal Revenue Service. Included in other (income) expense, net is a \$396 million gain on the divestiture of certain ophthalmic products in several international markets.

(4) Represents the estimated tax impact on the reconciling items.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2b

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 31,755					\$ 31,755
Costs, Expenses and Other						
Materials and production	13,019	4,270	377		4,647	8,372
Marketing and administrative	8,681	153	143	193	489	8,192
Research and development	4,897	36	175		211	4,686
Restructuring costs	664		664		664	-
Equity income from affiliates	(241)					(241)
Other (income) expense, net	(737)	93		(1,132)	(1,039)	302
Income Before Taxes	5,472	(4,552)	(1,359)	939	(4,972)	10,444
Taxes on Income	865				(1,809) ⁽⁴⁾	2,674
Net Income	4,607				(3,163)	7,770
Less: Net Income (Loss) Attributable to Noncontrolling Interests	3	(56)			(56)	59
Net Income Attributable to Merck & Co., Inc.	\$ 4,604				\$ (3,107)	\$ 7,711
Earnings per Common Share Assuming Dilution	\$ 1.57					\$ 2.62
Average Shares Outstanding Assuming Dilution	2,942					2,942
Tax Rate	15.8%					25.6%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$3.2 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$1.1 billion of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges primarily related to the company's joint venture with Supera. Amount included in other (income) expense, net is a goodwill impairment charge related to the joint venture with Supera. Amount included in net income (loss) attributable to non-controlling interests represents the portion of intangible asset and goodwill impairment charges related to the joint venture with Supera that are attributable to non-controlling interests.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Amount included in marketing and administrative expenses represents an additional year of expense related to the healthcare reform fee in accordance with final regulations issued in the third quarter by the Internal Revenue Service. Included in other (income) expense, net is a \$396 million gain on the divestiture of certain ophthalmic products in several international markets and a \$741 million net gain related to AstraZeneca's option exercise.

(4) Represents the estimated tax impact on the reconciling items, including a net benefit of approximately \$517 million recorded in connection with AstraZeneca's option exercise, as well as a benefit of approximately \$300 million associated with a capital loss generated in the first quarter.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
THIRD QUARTER 2013
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2c

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 11,032				\$ 11,032
Costs, Expenses and Other					
Materials and production	4,104	1,176	57	1,233	2,871
Marketing and administrative	2,803	20	31	51	2,752
Research and development	1,660		9	9	1,651
Restructuring costs	870		870	870	-
Equity income from affiliates	(102)				(102)
Other (income) expense, net	172				172
Income Before Taxes	1,525	(1,196)	(967)	(2,163)	3,688
Taxes on Income	375			(558) ⁽³⁾	933
Net Income	1,150			(1,605)	2,755
Less: Net Income Attributable to Noncontrolling Interests	26				26
Net Income Attributable to Merck & Co., Inc.	\$ 1,124			\$ (1,605)	\$ 2,729
Earnings per Common Share Assuming Dilution	\$ 0.38				\$ 0.92
Average Shares Outstanding Assuming Dilution	2,960				2,960
Tax Rate	24.6%				25.3%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions. Amounts included in marketing and administrative expenses reflect merger integration costs.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items, as well as a net benefit of approximately \$165 million related to the settlements of certain federal income tax issues.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
NINE MONTHS ENDED SEPTEMBER 30, 2013
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2d

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items	Adjustment Subtotal	Non-GAAP
Sales	\$ 32,713					\$ 32,713
Costs, Expenses and Other						
Materials and production	12,347	3,875	193		4,068	8,279
Marketing and administrative	8,929	62	64		126	8,803
Research and development	5,668	264	38		302	5,366
Restructuring costs	1,144		1,144		1,144	-
Equity income from affiliates	(351)					(351)
Other (income) expense, net	656			(13)	(13)	669
Income Before Taxes	4,320	(4,201)	(1,439)	13	(5,627)	9,947
Taxes on Income	618				(1,406) ⁽³⁾	2,024
Net Income	3,702				(4,221)	7,923
Less: Net Income Attributable to Noncontrolling Interests	79					79
Net Income Attributable to Merck & Co., Inc.	\$ 3,623				\$ (4,221)	\$ 7,844
Earnings per Common Share Assuming Dilution	\$ 1.20					\$ 2.61
Average Shares Outstanding Assuming Dilution	3,007					3,007
Tax Rate	14.3%					20.3%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$3.5 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$330 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs. Amounts included in research and development expenses represent in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items, as well as net benefits of approximately \$325 million related to the settlements of certain federal income tax issues.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)

Table 3

	2014				2013						% Change	% Change
	1Q	2Q	3Q	Sep YTD	1Q	2Q	3Q	Sep YTD	4Q	Full Year	3Q	Sep YTD
TOTAL SALES ⁽¹⁾	\$10,264	\$10,934	\$10,557	\$31,755	\$10,671	\$11,010	\$11,032	\$32,713	\$11,319	\$44,033	-4	-3
PHARMACEUTICAL	8,451	9,087	9,134	26,672	8,891	9,310	9,475	27,677	9,760	37,437	-4	-4
Primary Care and Women's Health												
Cardiovascular												
Zetia	611	717	660	1,988	629	650	662	1,941	716	2,658		2
Vytorin	361	417	369	1,146	394	417	396	1,207	436	1,643	-7	-5
Diabetes												
Januvia / Janumet	1,334	1,577	1,439	4,350	1,293	1,547	1,369	4,208	1,624	5,833	5	3
General Medicine & Women's Health												
NuvaRing	168	178	186	531	151	171	170	492	193	686	9	8
Implanon / Nexplanon	102	119	158	379	84	102	96	282	120	403	65	34
Dulera	102	103	124	328	68	79	82	229	95	324	51	43
Follistim AQ	110	102	97	309	122	134	124	380	101	481	-22	-19
Hospital and Specialty												
Hepatitis												
PegIntron	112	103	84	300	126	142	104	372	124	496	-19	-19
VICTRELIS	59	46	27	132	110	116	121	347	81	428	-78	-62
HIV												
Isentress	390	453	412	1,255	362	412	427	1,201	442	1,643	-3	4
Acute Care												
Cancidas	166	156	183	505	162	163	151	477	183	660	21	6
Invanz	114	134	141	390	110	120	130	360	128	488	9	8
Noxafil	74	98	107	280	65	71	75	212	98	309	42	32
Bridion	73	82	90	245	63	69	75	206	82	288	20	19
Primaxin	71	81	91	243	84	85	88	256	79	335	4	-5
Immunology												
Remicade	604	607	604	1,815	549	527	574	1,651	620	2,271	5	10
Simponi	157	174	170	500	108	120	126	354	146	500	35	41
Other												
Cosopt / Trusopt	99	100	34	232	105	103	104	313	103	416	-68	-26
Oncology												
Emend	122	144	136	402	116	135	123	373	134	507	11	8
Temodar	83	93	88	264	216	219	162	596	111	708	-46	-56
Diversified Brands												
Respiratory												
Nasonex	312	258	261	830	385	325	297	1,008	327	1,335	-12	-18
Singulair	271	284	218	773	337	281	280	898	298	1,196	-22	-14
Claritinex	62	69	49	180	61	64	54	180	55	235	-10	
Other												
Cozaar / Hyzaar	205	214	195	614	267	255	238	760	246	1,006	-18	-19
Arcoxia	128	141	132	400	121	121	112	354	131	484	18	13
Fosamax	123	121	114	358	137	144	140	421	139	560	-19	-15
Propecia	74	58	66	197	68	67	71	206	77	283	-7	-4
Zocor	64	69	61	194	82	74	65	221	79	301	-6	-12
Remeron	50	40	47	137	52	53	44	150	56	206	7	-8
Vaccines												
Gardasil	383	409	590	1,382	390	383	665	1,438	394	1,831	-11	-4
ProQuad, M-M-R II and Varivax	280	326	421	1,027	272	339	421	1,032	273	1,306		-1
RotaTeq	169	147	174	490	162	144	201	507	129	636	-14	-3
Zostavax	142	156	181	479	168	141	185	494	264	758	-2	-3
Pneumovax 23	101	102	197	400	111	108	193	412	241	653	2	-3
Other Pharmaceutical ⁽²⁾	1,175	1,209	1,228	3,617	1,361	1,430	1,350	4,139	1,435	5,570	-9	-13
ANIMAL HEALTH	813	872	885	2,569	840	851	800	2,491	871	3,362	11	3
CONSUMER CARE ⁽³⁾	546	583	401	1,531	571	490	443	1,504	390	1,894	-9	2
Claritin OTC	170	153	110	433	177	78	123	379	92	471	-11	14
Other Revenues ⁽⁴⁾	454	392	137	983	369	359	314	1,041	298	1,340	-56	-5
Astra	147	316	1	465	262	245	220	727	193	920	-99	-36

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$98 million, \$76 million and \$116 million for the first, second and third quarters of 2014, respectively. Other Vaccines sales included in Other Pharmaceutical were \$53 million, \$86 million, \$127 million, and \$101 million for the first, second, third, and fourth quarters of 2013, respectively.

⁽³⁾ The decrease in Consumer Care sales in the second quarter and full year of 2013 resulted from the termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

⁽⁴⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the company divested a substantial portion of its third-party manufacturing sales. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products. Other revenues in the first quarter and September YTD 2014 include \$232 million of revenue recognized in connection with the sale of U.S. Saphris rights. In addition, Other revenues in the fourth quarter and full year of 2013 reflect \$50 million of revenue for the out-license of a pipeline compound.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2014
(AMOUNTS IN MILLIONS)

Page 8

Table 3a

	Global			U.S.			International		
	3Q 2014	3Q 2013	% Change	3Q 2014	3Q 2013	% Change	3Q 2014	3Q 2013	% Change
TOTAL SALES ⁽¹⁾	\$10,557	\$11,032	-4	\$4,409	\$4,905	-10	\$6,148	\$6,127	
PHARMACEUTICAL	9,134	9,475	-4	3,837	4,148	-8	5,297	5,327	-1
Primary Care and Women's Health									
Cardiovascular									
Zetia	660	662		361	369	-2	298	293	2
Vytorin	369	396	-7	133	165	-19	236	232	2
Diabetes & Obesity									
Januvia / Janumet	1,439	1,369	5	740	701	6	698	668	4
General Medicine & Women's Health									
NuvaRing	186	170	9	119	106	12	67	64	4
Implanon / Nexplanon	158	96	65	93	50	86	65	46	42
Dulera	124	82	51	117	78	51	6	4	61
Follistim AQ	97	124	-22	39	55	-29	58	69	-16
Hospital and Specialty									
Hepatitis									
PegIntron	84	104	-19	4	9	-59	81	95	-15
Victrelis	27	121	-78		45	*	27	75	-64
HIV									
Isentress	412	427	-3	207	227	-9	205	199	3
Acute Care									
Candidas	183	151	21	4	7	-49	179	144	24
Invanz	141	130	9	72	70	3	69	59	17
Noxafil	107	75	42	40	23	73	67	52	29
Bridion	90	75	20				90	75	20
Primaxin	91	88	4	1	8	-93	91	80	13
Immunology									
Remicade	604	574	5				604	574	5
Simponi	170	126	35				170	126	35
Other									
Cosopt / Trusopt	34	104	-68	1	5	-84	33	100	-67
Oncology									
Emend	136	123	11	80	73	9	56	49	13
Temodar	88	162	-46	1	71	-99	87	91	-4
Diversified Brands									
Respiratory									
Nasonex	261	297	-12	154	179	-14	107	118	-9
Singular	218	280	-22	5	29	-83	214	252	-15
Clarinet	49	54	-10	7	6	4	42	48	-12
Other									
Cozaar / Hyzaar	195	238	-18	6	11	-44	188	227	-17
Arcoxia	132	112	18				132	112	18
Fosamax	114	140	-19	3	7	-52	111	133	-17
Propecia	66	71	-7	5	7	-30	61	64	-4
Zocor	61	65	-6	5	6	-14	56	59	-5
Remeron	47	44	7	1	1	-8	46	43	7
Vaccines									
Gardasil	590	665	-11	511	548	-7	79	117	-33
ProQuad, M-M-R II and Varivax	421	421		377	386	-2	44	35	26
RotaTeq	174	201	-14	126	154	-19	48	47	3
Zostavax	181	185	-2	149	169	-12	32	16	*
Pneumovax 23	197	193	2	150	149	1	48	44	7
Other Pharmaceutical ⁽²⁾	1,228	1,350	-9	326	433	-25	902	916	-2
ANIMAL HEALTH	885	800	11	216	208	4	669	591	13
CONSUMER CARE	401	443	-9	262	282	-7	139	160	-13
Claritin OTC	110	123	-11	75	90	-17	35	33	4
Other Revenues ⁽³⁾	137	314	-56	94	266	-65	43	48	-10
Astra	1	220	-99	1	220	-99			

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$116 million and \$127 million on a global basis for third quarter 2014 and 2013, respectively.

⁽³⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the company divested a substantial portion of its third-party manufacturing sales. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2014
(AMOUNTS IN MILLIONS)

Page 9

Table 3b

	Global			U.S.			International		
	Sep YTD 14	Sep YTD 13	% Change	Sep YTD 14	Sep YTD 13	% Change	Sep YTD 14	Sep YTD 13	% Change
TOTAL SALES ⁽¹⁾	\$31,755	\$32,713	-3	\$12,983	\$13,727	-5	\$18,772	\$18,987	-1
PHARMACEUTICAL	26,672	27,677	-4	10,429	11,093	-6	16,243	16,584	-2
Primary Care and Women's Health									
Cardiovascular									
Zetia	1,988	1,941	2	1,093	1,054	4	895	887	1
Vytorin	1,146	1,207	-5	410	491	-16	736	716	3
Diabetes & Obesity									
Januvia / Janumet	4,350	4,208	3	2,229	2,167	3	2,121	2,041	4
General Medicine & Women's Health									
NuvaRing	531	492	8	334	303	10	198	190	4
Implanon / Nexplanon	379	282	34	220	144	53	159	139	14
Dulera	328	229	43	312	218	43	16	11	52
Follistim AQ	309	380	-19	103	158	-34	206	222	-7
Hospital and Specialty									
Hepatitis									
PegIntron	300	372	-19	16	31	-49	284	341	-17
Victrelis	132	347	-62	5	134	-96	128	213	-40
HIV									
Isentress	1,255	1,201	4	626	633	-1	629	569	11
Acute Care									
Cancidas	505	477	6	15	22	-33	491	455	8
Invanz	390	360	8	195	185	5	195	175	11
Noxafil	280	212	32	95	63	50	185	149	24
Bridion	245	206	19				245	206	19
Primaxin	243	256	-5	4	15	-76	239	241	-1
Immunology									
Remicade	1,815	1,651	10				1,815	1,651	10
Simponi	500	354	41				500	354	41
Other									
Cosopt / Trusopt	232	313	-26	2	13	-86	230	299	-23
Oncology									
Emend	402	373	8	228	213	7	174	160	9
Temodar	264	596	-56	5	287	-98	259	310	-16
Diversified Brands									
Respiratory									
Nasonex	830	1,008	-18	428	506	-15	402	501	-20
Singulair	773	898	-14	18	45	-60	755	853	-12
Clarinet	180	180		18	14	32	162	166	-2
Other									
Cozaar / Hyzaar	614	760	-19	20	26	-23	594	734	-19
Arcoxia	400	354	13				400	354	13
Fosamax	358	421	-15	13	16	-21	346	405	-15
Propecia	197	206	-4	14	18	-22	183	188	-3
Zocor	194	221	-12	15	18	-16	179	204	-12
Remeron	137	150	-8	3	4	-20	134	146	-8
Vaccines									
Gardasil	1,382	1,438	-4	1,075	1,047	3	307	390	-21
ProQuad, M-M-R II and Varivax	1,027	1,032	-1	894	933	-4	133	99	34
RotaTeq	490	507	-3	357	382	-7	133	125	6
Zostavax	479	494	-3	393	443	-11	86	51	69
Pneumovax 23	400	412	-3	318	315	1	82	97	-15
Other Pharmaceutical ⁽²⁾	3,617	4,139	-13	971	1,195	-19	2,642	2,942	-10
ANIMAL HEALTH	2,569	2,491	3	578	658	-12	1,992	1,833	9
CONSUMER CARE ⁽³⁾	1,531	1,504	2	1,058	1,073	-1	473	431	10
Claritin OTC	433	379	14	324	343	-6	109	36	*
Other Revenues ⁽⁴⁾	983	1,041	-5	919	902	2	64	139	-54
Astra	465	727	-36	465	727	-36			

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$291 million and \$267 million on a global basis for September YTD 2014 and 2013, respectively.

⁽³⁾ September YTD 2013 includes a reduction to Consumer Care sales that reflects the termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

⁽⁴⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the company divested a substantial portion of its third-party manufacturing sales. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products. Other revenues in September YTD 2014 include \$232 million of revenue recognized in connection with the sale of U.S. Saphris rights.

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)

Table 3c

	2014				2013						% Change 3Q	% Change Sep YTD
	1Q 2014	2Q 2014	3Q 2014	Sep YTD	1Q 2013	2Q 2013	3Q 2013	Sep YTD	4Q 2013	Full Year		
TOTAL PHARMACEUTICAL	\$8,451	\$9,087	\$9,134	\$26,672	\$8,891	\$9,310	\$9,475	\$27,677	\$9,760	\$37,437	-4	-4
United States	3,130	3,462	3,837	10,429	3,256	3,689	4,148	11,093	3,761	14,854	-8	-6
% Pharmaceutical Sales	37.0%	38.1%	42.0%	39.1%	36.6%	39.6%	43.8%	40.1%	38.5%	39.7%		
Europe ⁽¹⁾	2,478	2,537	2,297	7,312	2,465	2,343	2,276	7,084	2,535	9,619	1	3
% Pharmaceutical Sales	29.3%	27.9%	25.2%	27.4%	27.7%	25.2%	24.0%	25.6%	26.0%	25.7%		
Japan	835	859	730	2,423	1,034	948	893	2,875	1,074	3,949	-18	-16
% Pharmaceutical Sales	9.9%	9.5%	8.0%	9.1%	11.6%	10.2%	9.4%	10.4%	11.0%	10.5%		
Asia Pacific	809	840	878	2,528	822	874	799	2,495	870	3,365	10	1
% Pharmaceutical Sales	9.6%	9.2%	9.6%	9.5%	9.2%	9.4%	8.4%	9.0%	8.9%	9.0%		
China	282	309	318	909	271	297	242	810	293	1,103	32	12
Latin America	538	668	673	1,879	596	676	628	1,899	667	2,567	7	-1
% Pharmaceutical Sales	6.4%	7.3%	7.4%	7.0%	6.7%	7.3%	6.6%	6.9%	6.8%	6.9%		
Eastern Europe/Middle East Africa	415	459	443	1,317	439	479	431	1,349	534	1,883	3	-2
% Pharmaceutical Sales	4.9%	5.1%	4.9%	4.9%	4.9%	5.1%	4.5%	4.9%	5.5%	5.0%		
Canada	200	218	218	636	245	257	253	755	276	1,030	-14	-16
% Pharmaceutical Sales	2.4%	2.4%	2.4%	2.4%	2.8%	2.8%	2.7%	2.7%	2.8%	2.8%		
Other	46	44	58	148	34	45	47	127	43	170	22	16
% Pharmaceutical Sales	0.5%	0.5%	0.6%	0.6%	0.4%	0.5%	0.5%	0.5%	0.4%	0.5%		

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
THIRD QUARTER 2014
EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4

EQUITY INCOME FROM AFFILIATES

	3Q14	3Q13	Sep YTD 2014	Sep YTD 2013
ASTRAZENECA LP ⁽¹⁾	\$ -	\$ 72	\$ 192	\$ 302
Other ⁽²⁾	24	30	49	49
TOTAL	\$ 24	\$ 102	\$ 241	\$ 351

⁽¹⁾ Effective July 1, 2014, the Company no longer records equity income from AstraZeneca LP.

⁽²⁾ Includes results for Sanofi Pasteur MSD.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a "NET" basis.

	3Q14	3Q13	Sep YTD 2014	Sep YTD 2013
GARDASIL	\$ 73	\$ 87	\$ 192	\$ 221
ZOSTAVAX	60	41	97	41
FLU VACCINES	92	93	92	93
OTHER VIRAL VACCINES	21	23	67	79
ROTATEQ	16	14	48	41
HEPATITIS VACCINES	10	8	27	23
Other Vaccines	125	126	304	331
TOTAL SANOFI PASTEUR MSD SALES	\$ 397	\$ 392	\$ 827	\$ 829

OTHER (INCOME) EXPENSE, NET

	3Q14	3Q13	Sep YTD 2014	Sep YTD 2013
INTEREST INCOME	\$ (69)	\$ (67)	\$ (190)	\$ (189)
INTEREST EXPENSE	191	215	567	600
EXCHANGE LOSSES	61	11	114	278
Other, net ⁽¹⁾	(325)	13	(1,228)	(33)
TOTAL	\$ (142)	\$ 172	\$ (737)	\$ 656

⁽¹⁾ Other, net in the third quarter and first nine months of 2014 includes a \$396 million gain on the sale of certain ophthalmic products in several international markets. Other, net in the first nine months of 2014 also includes a \$741 million gain on AstraZeneca's option exercise.